Investigation of Safety, Tolerability and Pharmacokinetic Properties of Multiple Doses of Oral NNC0487-0111 in Japanese Participants With Obesity
Latest Information Update: 06 Mar 2024
At a glance
- Drugs Amycretin (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 20 Dec 2023 Status changed from active, no longer recruiting to completed.
- 24 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 26 Sep 2023 New trial record